MORRISVILLE, N.C., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today released its 2021 Sustainability Report. The Report spotlights how the Company and its more than 29,000 employees have acted on their shared purpose to lead with a product development mindset and expand the Company’s Environmental, Social and Governance (ESG) impact. The Company continues to advance external and internal initiatives associated with achieving its Vision – Shortening the Distance from Lab to Life®.

The 2021 Report reflects the Company’s ongoing commitment to embed Diversity, Equity and Inclusion (DE&I) in all core business practices from clinical trials to product launch strategies to be more representative of patient populations. Other focus areas include developing and retaining top talent through a Total Self culture where employees are encouraged to be their authentic selves, minimizing environmental impact and maintaining strong governance processes.

“The pandemic, more than ever, demonstrated why our work is so important, shining a light on the value of clinical trials and the importance of equitable access to medicines,” said Michelle Keefe, CEO, Syneos Health. “We believe that by diversifying and strengthening our knowledge of real-word challenges, we will create better outcomes for patients worldwide.”

Report Highlights:

“As a company purpose-built to challenge the old ways of biopharmaceutical development, the initiatives outlined in our 2021 Sustainability Report are the foundation of who we are as a company – from increasing diversity in clinical trials to continuing to build an inclusive culture,” added Keefe.

The full 2021 Sustainability Report can be found on the Company’s website.

About Syneos Health
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. We lead with a product development mindset, strategically integrating clinical development, medical affairs and commercial capabilities to address modern market realities.

We bring together more than 29,000 minds, across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.

Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.

To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.

Investor Relations Contact: 
Ronnie Speight
Senior Vice President, Investor Relations
+1 919 745 2745
Investor.Relations@syneoshealth.com
Press/Media Contact:
Gary Gatyas
Executive Director, External Communications
+1 908 763 3428
gary.gatyas@syneoshealth.com